June 22, 2015
BioTissue Hosts Educational Events on Advances in the Treatment of Dry Eye and Lid Margin Disease at Optometry’s Meeting® 2015
Innovative products rejuvenate the ocular surface and facilitate
MIAMI, Fla., June 22, 2015 – BioTissue®, Inc., the industry leader in regenerative tissue therapies and ocular hygiene products for lid margin and ocular surface diseases, will host key educational events and training sessions highlighting advances in the treatment of dry eye and lid margin diseases at this year’s Optometry’s Meeting being held June 24-28, 2015 in Seattle, WA. BioTissue’s range of products facilitate quality healing on the ocular surface allowing patients to heal faster with improved clinical outcomes.
BioTissue will host a Dry Eye Center of Excellence Instructional Course to provide an overview of a proven approach to implement its PROKERA® biologic corneal bandage for the treatment of Dry Eye Workshop (DEWS) level 3 and 4 patients with corneal involvement. Presenters Douglas Devries, OD, Eye Care Associates of Nevada and Nick Pisani, Director of Clinical Implementation, BioTissue will discuss patient selection, workflow protocol, and practice management. They will also conduct a wet-lab and demonstrate a live PROKERA® insertion and removal procedure, review study data on PROKERA® for Dry Eye and provide guidance on implementation, enhancing the patient experience and improved practice revenue. The event will be held on Friday, June 26 from 6:30pm – 8:30 pm at the Grand Hyatt Seattle.
“Treating patients with chronic Dry Eye can be challenging particularly for those patients with more severe cases with corneal involvement,” said Douglas Devries, OD. “BioTissue’s PROKERA® and its full range of products for dry eye go beyond symptom management to rejuvenate the ocular surface and help patients see and feel better.”
BioTissue will hold live demonstrations of PROKERA® insertion/removal and Cliradex® Complete application in its booth #919. BioTissue also provided an educational grant to the Optometry’s meeting to support sessions and educational courses on the important area of Ocular Surface/Lid Margin Disease. These include “Sutureless Amniotic Membranes: When and How to Use Them” and “How to Take the Recurrent out of Recurrent Corneal Erosion Syndrome,” presented by Nicholas Colatrella, OD and Jeffrey Varanelli, OD; and an Amniotic Membrane Workshop presented by Doug Devries, OD.
BioTissue, Inc., a subsidiary of TissueTech, is a privately held ophthalmic biotechnology company that develops innovative wound healing and hygiene solutions for the prevention and treatment of ocular surface diseases and disorders. BioTissue provides a comprehensive line of cryopreserved amniotic membrane ocular wound healing products, including AmnioGraft®, a biologic ocular transplantation graft; AmnioGuard®, a biologic glaucoma shunt tube graft; and the PROKERA® family of biologic corneal bandage devices. These products incorporate human amniotic membrane processed with the Company’s proprietary CryoTek® method proven to preserve the biological properties of amniotic membrane and umbilical cord tissue essential for anti-inflammatory and anti-scarring effects compared with the dehydration method that drastically alters the structural and biological integrity of this tissue.1 BioTissue also developed and markets the Cliradex® line of products, a natural lid, lash and facial cleanser with 4-Terpineol, the active component of tea tree oil (TTO), for the management of symptoms in ocular diseases such as blepharitis, demodex, and rosacea.